{"organizations": [], "uuid": "f9facada1aad54aa4e628c601a1936ca231d4f84", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-immunocellular-therapeutics-announ/brief-immunocellular-therapeutics-announces-review-of-strategic-alternatives-idUSASB0C6WS", "country": "US", "domain_rank": 408, "title": "BRIEF-Immunocellular Therapeutics Announces Review Of Strategic Alternatives", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-22T13:11:00.000+02:00", "replies_count": 0, "uuid": "f9facada1aad54aa4e628c601a1936ca231d4f84"}, "author": "", "url": "https://www.reuters.com/article/brief-immunocellular-therapeutics-announ/brief-immunocellular-therapeutics-announces-review-of-strategic-alternatives-idUSASB0C6WS", "ord_in_thread": 0, "title": "BRIEF-Immunocellular Therapeutics Announces Review Of Strategic Alternatives", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-immunocellular therapeutics announces review of strategic alternatives", "sentiment": "negative"}, {"name": "brief-immunocellular therapeutics", "sentiment": "negative"}, {"name": "immunocellular therapeutics ltd", "sentiment": "none"}, {"name": "ladenburg thalmann & co", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 11 AM / Updated 9 minutes ago BRIEF-Immunocellular Therapeutics Announces Review Of Strategic Alternatives Reuters Staff Feb 22 (Reuters) - Immunocellular Therapeutics Ltd: * IMMUNOCELLULAR THERAPEUTICS ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES * IMMUNOCELLULAR THERAPEUTICS ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES * IMMUNOCELLULAR THERAPEUTICS - RETAINED LADENBURG THALMANN & CO AS STRATEGIC FINANCIAL ADVISOR TO ASSIST IN REVIEW OF BUSINES, ASSETS * IMMUNOCELLULAR THERAPEUTICS - REVIEW OF STRATEGIC OPPORTUNITIES COULD INCLUDE POTENTIAL SALE OR MERGER OF COMPANY Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-22T13:11:00.000+02:00", "crawled": "2018-02-22T13:30:32.002+02:00", "highlightTitle": ""}